Argatroban: A review of its use in the management of heparin-induced thrombocytopenia

American Journal of Cardiovascular Drugs

Volumn 9, Issue 4, 2009, Pages 261-282

  Dhillon, Sohita ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARG 911; ARGATROBAN; DIGOXIN; ERYTHROMYCIN; HEPARIN; HIRULOG; LEPIRUDIN; LIDOCAINE; PARACETAMOL; PHENPROCOUMON; UNCLASSIFIED DRUG; WARFARIN;

ANGINA PECTORIS; ANTICOAGULATION; BACKACHE; BLEEDING; BLEEDING TIME; BRAIN HEMORRHAGE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; CRITICALLY ILL PATIENT; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EVENT FREE SURVIVAL; FEVER; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEART ARREST; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMATOMA; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARINIZATION; HUMAN; HYPOKALEMIA; HYPOTENSION; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; KAPLAN MEIER METHOD; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; POST HOC ANALYSIS; PRIORITY JOURNAL; PURPURA; RASH; RETROPERITONEAL HEMORRHAGE; REVIEW; SEPSIS; STEADY STATE; STROKE; THORAX PAIN; THROMBOCYTE AGGREGATION; THROMBOPHLEBITIS; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; HEPARIN; HUMANS; PIPECOLIC ACIDS; THROMBIN; THROMBOCYTOPENIA; THROMBOSIS;

EID: 70349113093     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/1120090-000000000-00000     Document Type: Review

References (81)

1. Jang IK, Hursting MJ. When heparins promote thrombosis: review of heparin-induced thrombocytopenia. Circulation 2005 May 24; 111 (20): 2671-2683
2. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis, frequency, avoidance and management. Drug Saf 1997 Nov; 17 (5): 325-341
3. Hirsh J, Heddle N, Kelton JG. Treatment of heparin-induced thrombocytopenia: a critical review. Arch Intern Med 2004 Feb 23; 164 (4): 361-369
4. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995 May 18; 332 (20): 1330-1335
5. Warkentin TE, Roberts RS, Hirsh J, et al. An improved definition of immune heparin-induced thrombocytopenia in postoperative orthopedic patients. Arch Intern Med 2003 Nov 10; 163 (20): 2518-2524
6. Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood 2003 Apr 15; 101 (8): 2955-2959
7. Wallis DE, Workman DL, Lewis BE, et al. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999 Jun; 106 (6): 629-635
8. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996 Nov; 101 (5): 502-507
9. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003 Aug 11; 163 (15): 1849-1856
10. Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008 Jun; 133 (6 Suppl.): 340S-80S
11. GlaxoSmithKline. Argatroban injection: US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/scripts/cder/ drugsatfda/ index.cfm?fuseaction=Search.Label-ApprovalHistory [Accessed 2009 Feb 16]
12. McKeage K, Plosker GL. Argatroban. Drugs 2001; 61 (4): 515-522
13. Kondo LM, Wittkowsky AK, Wiggins BS. Argatroban for prevention and treatment of thromboembolism in heparin-induced thrombocytopenia. Ann Pharmacother 2001 Apr; 35 (4): 440-451
14. Hursting MJ, Alford KL, Becker J-CP, et al. Novastan(brand of argatroban): a small-molecule, direct thrombin inhibitor. Semin Thromb Hemost 1997; 23 (6): 503-516
15. Kikumoto R, Tamao Y, Tezuka T, et al. Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl) sulfonyl]L-arginyl)]-2-piperidinecarboxylic acid. Biochemistry (Mosc) 1984 Jan 3; 23 (1): 85-90
16. Tanaka KA, Szlam F, Katori N, et al. The effects of argatroban on thrombin generation and hemostatic activation in vitro. Anesth Analg 2004 Nov; 99 (5): 1283-1289
17. Berry CN, Girardot C, Lecoffre C, et al. Effects of the synthetic thrombin inhibitor argatroban on fibrin-or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 1994 Sep; 72: 381-386
18. Hantgan RR, Jerome WG, Hursting MJ. No effect of clot age or thrombolysis on argatroban's inhibition of thrombin. Blood 1998 Sep 15; 92 (6): 2064-2074
19. Nielsen VG, Steenwyk BL, Gurley WQ, et al. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro. J Heart Lung Transplant 2006; 25 (6): 653-663
20. Young G, Yonekawa KE, Nakagawa PA, et al. Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation. Blood Coagul Fibrinolysis 2007 Mar; 18 (2): 97-103
21. Nielsen VG, Kirklin JK. Argatroban enhances fibrinolysis by differential inhibition of thrombin-mediated activation of thrombin activatable fibrinolysis inhibitor and factor XIII. Blood Coagul Fibrinolysis 2008 Dec; 19 (8): 793-800
22. Swan SK, St Peter JV, Lambrecht LJ, et al. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000 Jul; 20 (7): 756-770
23. Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001 Apr 10; 103 (14): 1838-1843
24. Gosselin RC, Dager WE, King JH, et al. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values. Am J Clin Pathol 2004 Apr; 121 (4): 593-599
25. Walenga JM, Koza MJ, Lewis BE, et al. Relative heparin-induced thrombocytopenia potential of low molecular weight heparins and new antithrombotic agents. Clin Appl Thromb Hemost 1996; 2 Suppl. 1: S21-7
26. Lewis BE, Matthai JrWH, Cohen M, et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002 Oct; 57 (2): 177-184
27. Walenga JM, Ahmad S, Hoppensteadt D, et al. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb Res 2002 Mar 1; 105 (5): 401-405
28. Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000 Mar; 20 (3): 318-329
29. Murray PT, Reddy BV, Grossman EJ, et al. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int 2004 Dec; 66 (6): 2446-2453
30. Sheth SB, DiCicco RA, Hursting MJ, et al. Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin [published erratum appears in Thromb Haemost 2001 Aug;86 (2):727]. Thromb Haemost 2001 Mar; 85 (3): 435-440
31. Harder S, Graff J, Klinkhardt U, et al. Transition from argatroban to oral anticoagulation with phenprocoumon or acenocoumarol: effects on pro-thrombin time, activated partial thromboplastin time, and ecarin clotting time. Thromb Haemost 2004 Jun; 91 (6): 1137-1145
32. Tran JQ, Di Cicco RA, Sheth SB, et al. Assessment of the potential pharmacokinetic and pharmacodynamic interactions between erythromycin and argatroban. J Clin Pharmacol 1999 May; 39 (5): 513-519
33. Matsuo T, Chikahira Y, Yamada T, et al. Effect of synthetic thrombin inhibitor (MD805) as an alternative drug on heparin induced thrombocytopenia during hemodialysis. Thromb Res 1988 Oct 15; 52 (2): 165-171
34. Winn MJ, Jain K, Ku DD. Argatroban and inhibition of the vasomotor actions of thrombin. J Cardiovasc Pharmacol 1993 Nov; 22 (5): 754-760
35. Hijikata-Okunomiya A, Nakaya Y, Inoue N, et al. Effects of argatroban on thrombin-induced events in cultured vascular smooth muscle cells. Thromb Res 2000 Feb 15; 97 (4): 257-262
36. Center for Drug Evaluation and Research. Argatroban: clinical pharmacology and biopharmaceutics review [online]. Available from URL: http:// www.fda.gov/cder/foi/nda/2000/20-883-Acova.htm [Accessed 2009 Mar 24]
37. Clarke RJ, Mayo G, FitzGerald GA, et al. Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 1991 May; 83 (5): 1510-1518
38. Brown PM, Hursting MJ. Lack of pharmacokinetic interactions between argatroban and warfarin. Am J Health Syst Pharm 2002 Nov 1; 59 (21): 2078-2083
39. Inglis AM, Sheth SB, Hursting MJ, et al. Investigation of the interaction between argatroban and acetaminophen, lidocaine, or digoxin. Am J Health Syst Pharm 2002 Jul 1; 59 (13): 1258-1266
40. Lewis BE, Wallis DE, Hursting MJ, et al. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest 2006 Jun; 129 (6): 1407-1416
41. LaMonte MP, Brown PM, Hursting MJ. Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy. Crit Care Med 2004; 32 (4): 976-980
42. Jang IK, Hursting MJ, McCollum D. Argatroban therapy in patients with coronary artery disease and heparin-induced thrombocytopenia. Cardiology 2008; 109 (3): 172-176
43. Gray A, Wallis DE, Hursting MJ, et al. Argatroban therapy for heparin-induced thrombocytopenia in acutely ill patients. Clin Appl Thromb Hemost 2007 Oct; 13 (4): 353-361
44. Levine RL, Hursting MJ, McCollum D. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction. Chest 2006 May; 129 (5): 1167-1175
45. Matthai Jr WH, Hursting MJ, Lewis BE, et al. Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia. Thromb Res 2005; 116 (2): 121-126
46. Bartholomew JR, Hursting MJ. Transitioning from argatroban to warfarin in heparin-induced thrombocytopenia: an analysis of outcomes in patients with elevated international normalized ratio (INR). J Thromb Thrombolysis 2005 Jun; 19 (3): 183-188
47. Young G, Boshkov LK. Prospective study of direct thrombin inhibition with argatroban in pediatric patients requiring nonheparin anticoagulation [abstract no. 1868]. Blood 2007 Nov; 110 (11): 553
48. Topol EJ, Califf RM, Weisman HF. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994 Apr 9; 343 (8902): 881-886
49. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997 Jun 12; 336 (24): 1689-1696
50. The CAPTURE investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997 May 17; 349 (9063): 1429-1435
51. LaMonte MP, Nash ML, Wang DZ, et al. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study. Stroke 2004 Jul; 35 (7): 1677-1682
52. Rice L. Heparin-induced thrombocytopenia: myths and misconceptions (that will cause trouble for you and your patient). Arch Intern Med 2004 Oct 11; 164 (18): 1961-1964
53. Crespo EM, Oliveira GB, Honeycutt EF, et al. Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: the Complications After Thrombocytopenia Caused by Heparin (CATCH) registry. Am Heart J 2009 Apr; 157 (4): 651-657
54. Bayer HealthCare Pharmaceuticals Inc. Refludan (lepirudin rDNA for injection): US prescribing information [online]. Available from URL: http:// www.refludan.com/index.jsp [Accessed 2009 Apr 6]
55. Ben Venue Laboratories. Angiomax (bivalirudin): US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/scripts/ cder/drugsatfda/index.cfm?fuseaction=Search.Label-ApprovalHistory [Accessed 2009 Apr 6]
56. Kelton JG, Warkentin TE. Heparin-induced thrombocytopenia: a historical perspective. Blood 2008 Oct 1; 112 (7): 2607-2616
57. Warkentin TE. Management of heparin-induced thrombocytopenia: a critical comparison of lepirudin and argatroban. Thromb Res 2003; 110 (2-3): 73-82
58. Begelman SM, Hursting MJ, Aghababian RV, et al. Heparin-induced thromboctyopenia from venous thromboembolism treatment. J Intern Med 2005 Dec; 258 (6): 563-572
59. Guzzi LM, McCollum DA, Hursting MJ. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia. J Thromb Thrombolysis 2006 Dec; 22 (3): 169-176
60. Reddy BV, Grossman EJ, Trevino SA, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy. Ann Pharmacother 2005 Oct; 39 (10): 1601-1605
61. Hursting MJ, Dubb J, Verme-Gibboney CN. Argatroban anticoagulation in pediatric patients: a literature analysis. J Pediatr Hematol Oncol 2006 Jan; 28 (1): 4-10
62. Kelton JG, Hursting MJ, Heddle N, et al. Predictors of clinical outcome in patients with heparin-induced thrombocytopenia treated with direct thrombin inhibition. Blood Coagul Fibrinolysis 2008 Sep; 19 (6): 471-475
63. Hursting MJ, Verme-Gibboney CN. Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with argatroban: a retrospective study. J Cardiovasc Pharmacol 2008 Dec; 52 (6): 561-566
64. Greinacher A, Eichler P, Lubenow N, et al. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000 Aug 1; 96 (3): 846-851
65. Eichler P, Friesen HJ, Lubenow N, et al. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 2000 Oct 1; 96 (7): 2373-2378
66. Arnold RJ, Kim R, Tang B. The cost-effectiveness of argatroban treatment in heparin-induced thrombocytopenia: the effect of early versus delayed treatment. Cardiol Rev 2006 Jan 28; 14 (1): 7-13
67. Patrick AR, Winkelmayer WC, Avorn J, et al. Strategies for the management of suspected heparin-induced thrombocytopenia: a cost-effectiveness analysis. Pharmacoeconomics 2007; 25 (11): 949-961
68. Begelman SM, Baghdasarian SB, Singh IM, et al. Argatroban anticoagulation in intensive care patients: effects of heart failure and multiple organ system failure. J Intensive Care Med 2008 Sep 31; 23 (5): 313-320
69. Kodityal S, Nguyen PH, Kodityal A, et al. Argatroban for suspected heparin-induced thrombocytopenia: contemporary experience at a large teaching hospital. J Intensive Care Med 2006 Mar 30; 21 (2): 86-92
70. Kiser TH, Jung R, MacLaren R, et al. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia. Pharmacotherapy 2005 Dec; 25 (12): 1736-1745
71. de Denus S, Spinler SA. Decreased argatroban clearance unaffected by hemodialysis in anasarca. Ann Pharmacother 2003 Sep; 37 (9): 1237-1240
72. Reichert MG, MacGregor DA, Kincaid EH, et al. Excessive argatroban anticoagulation for heparin-induced thrombocytopenia. Ann Pharmacother 2003 May; 37 (5): 652-654
73. Beiderlinden M, Treschan TA, Gö rlinger K, et al. Argatroban anticoagulation in critically ill patients. Ann Pharmacother 2007 May; 41 (5): 749-754
74. Koster A, Buz S, Hetzer R, et al. Anticoagulation with argatroban in patients with heparin-induced thrombocytopenia antibodies after cardiovascular surgery with cardiopulmonary bypass: first results from the ARG-E03 trial. J Thorac Cardiovasc Surg 2006 Sep; 132 (3): 699-700
75. Hoffman WD, Czyz Y, McCollum DA, et al. Reduced argatroban doses after coronary artery bypass graft surgery. Ann Pharmacother 2008 Mar; 42 (3): 309-316
76. Keegan SP, Gallagher EM, Ernst NE, et al. Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia. Ann Pharmacother 2009 Jan; 43 (1): 19-27
77. Hursting MJ, Soffer J. Reducing harm associated with anticoagulation: practical considerations of argatroban therapy in heparin-induced thrombocytopenia. Drug Saf 2009; 32 (3): 203-218
78. Bartholomew JR, Pietrangeli CE, Hursting MJ. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients. Drugs Aging 2007; 24 (6): 489-499
79. Jang IK, Baron SJ, Hursting MJ, et al. Argatroban therapy in women with heparin-induced thrombocytopenia. J Womens Health (Larchmt) 2007 Jul 31; 16 (6): 895-901
80. Rice L, Hursting MJ, Baillie GM, et al. Argatroban anticoagulation in obese versus nonobese patients: implications for treating heparin-induced thrombocytopenia. J Clin Pharmacol 2007 Aug; 47 (8): 1028-1034
81. Hursting MJ, Jang IK. Effect of body mass index on Argatroban therapy during percutaneous coronary intervention. J Thromb Thrombolysis 2008 Jun; 25 (3): 273-279